Clinical Trial Update: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 [Phase 2]

View source ↗

Summary

Phase 2 platform trial evaluating novel regimens versus standard of care in non-small cell lung cancer (NSCLC), Sub-study 3, has completed with results posted. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2025-07-03